Pfizer, US ink $5.29 bln deal for Covid pills

Pfizer, US ink $5.29 bln deal for Covid pills The company has entered into a voluntary license agreement with the Medicines Patent Pool to help expand access in 95 low- and middle-income countries that account for approximately 53% of the world’s population, pending authorization or approval. If approved PAXLOVID™ (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2 https://ift.tt/eA8V8J